Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Summary

This phase II trial is studying how well sunitinib works in treating patients with recurrent or persistent leiomyosarcoma of the uterus. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start

2006-10

Primary completion

2007-06

Completion

2010-01

Drugs

Indications